Loading…
Hunan maker of transdermal medicated patches and topical drugs sold through Chinese pharmacies.
Hunan maker of transdermal medicated patches and topical drugs sold through Chinese pharmacies.
In one line: A small Chinese medicated-patch maker.
Moat: narrow (brand). Established patch brand with pharmacy distribution, though a niche OTC category.
Headquarters: Changsha, Hunan, China · Employees: 1,291
Size Hunan Warrant Pharmaceutical (688799.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $942M, the 2421st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥47.00 on 6 Nov 2026.
Performance Over six months the shares fell 19.9%, against -11.8% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 5.1% over the last twelve months (peer median -0.6%); the operating margin is 9.4% (peer median 2.7%).
Valuation It trades at 33.8× forward earnings against a peer median of 24.5× (2nd most expensive of 10).
Capital Return on invested capital runs 2.2 points below its cost of capital (6.1% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.45B | CN¥1.50B | CN¥1.39B | CN¥1.41B | CN¥1.28B |
| Revenue growth | — | +8% | -2% | +10% | — |
| Gross profit | CN¥812M | CN¥868M | CN¥820M | CN¥881M | CN¥844M |
| EBITDA | CN¥217M | CN¥216M | CN¥205M | CN¥265M | CN¥216M |
| Net income | CN¥232M | CN¥238M | CN¥164M | CN¥211M | CN¥183M |
| Free cash flow | -CN¥197M | -CN¥202M | -CN¥91.4M | CN¥119M | CN¥36.5M |
| Capital expenditure | CN¥606M | CN¥520M | CN¥234M | CN¥106M | CN¥132M |
| Total debt | CN¥782M | CN¥507M | CN¥165M | CN¥24.2M | CN¥13.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Hunan Warrant Pharmaceutical 688799.SS | $942M | -20% | +5% | 9% | 33.8× | n/a |
| Henan Lingrui Pharmaceutial 600285.SS | $2.02B | +7% | +5% | 22% | 15.9× | -4.8% |
| Shandong Buchang Pharmaceuticals 603858.SS | $2.31B | -7% | +4% | 10% | n/a | -2.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688799.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.3% | -7.3% | 7th lowest of 20 |
| 6-month return | -19.9% | -11.8% | 6th lowest of 20 |
| Distance from 52-week high | -27.9% | -32.5% | 9th highest of 21 |
| Revenue growth (TTM) | +5.1% | -0.6% | 8th highest of 18 |
| Operating margin | 9.4% | 2.7% | 7th highest of 18 |
| Forward P/E | 33.8× | 24.5× | 2nd most expensive of 10 |
| ROIC minus cost of capital | -2.2 pp | -2.4 pp | 9th highest of 17 |
| EV / EBITDA | 31.2× | 15.4× | 2nd most expensive of 7 |
| Net debt / EBITDA | 2.3× | 2.0× | 3rd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hunan Warrant Pharmaceutical 688799.SS | China | $942M | -20% | +5% | 9% | 33.8× | n/a | n/a |
| City Therapeutics CTY | United States | $944M | n/a | +388% | -442% | n/a | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $948M | -10% | -6% | 3% | n/a | -6.8% | -0.7% |
| Immatics IMTX | United States | $952M | -44% | -65% | -556% | n/a | n/a | n/a |
| Nxera Pharma 4565.T | Japan | $932M | +63% | +24% | 14% | 24.5× | 16.2% | +27.3% |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $930M | -24% | -6% | 5% | 41.1× | 33.2% | +4.2% |
| Dezhan Healthcare 000813.SZ | China | $928M | -18% | -10% | -121% | n/a | n/a | n/a |
| Oric Pharmaceuticals ORIC | United States | $914M | 0% | n/a | n/a | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $971M | +4% | +13% | 31% | 24.7× | 5.5% | +9.3% |
| Bide Pharmatech 688073.SS | China | $912M | +5% | +10% | 19% | 27.5× | 16.7% | +27.7% |
| Kissei Pharmaceutical 4547.T | Japan | $973M | -16% | +6% | 6% | 12.0× | n/a | n/a |
| Strides Pharma Science STAR.NS | India | $973M | -13% | +11% | 14% | 15.5× | 18.1% | +7.8% |
| Jiangsu Yahong Meditech 688176.SS | China | $973M | -12% | +15% | -172% | n/a | n/a | n/a |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $909M | -33% | -14% | -29% | n/a | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $909M | -65% | -11% | -3% | n/a | -1.2% | -39.5% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $907M | -12% | -25% | 2% | n/a | 16.2% | -0.2% |
| MoonLake Immunotherapeutics MLTX | United States | $981M | -32% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $983M | -7% | +2% | 24% | 24.4× | 10.2% | +13.4% |
| SSY 2005.HK | Hong Kong | $990M | +10% | -4% | 12% | 13.0× | 2.1% | -0.5% |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $894M | -8% | -1% | -2% | 30.6× | n/a | n/a |
| Savara SVRA | United States | $992M | -8% | n/a | n/a | n/a | n/a | n/a |